Senior Advisor Genia Long Publishes on the Role of Intellectual Property Protection and Incentives in Encouraging Biopharmaceutical Innovation
February 13, 2015
In an article published in Health Affairs, "The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation" (February 2015), Senior Advisor Genia Long and coauthors Henry Grabowski of Duke University and Joseph DiMasi of the Tufts Center for the Study of Drug Development at Tufts University address the role of patent protection, regulatory exclusivity, and other incentives in encouraging innovation in biopharmaceuticals. They consider ongoing discussion about how best to structure the balance between intellectual property protections to drive the development of new treatments, and generic utilization and price competition. The authors review the current landscape of general and targeted "push" and "pull" research and development incentives, as well as the advantages and disadvantages of alternatives to the patent-based system. In particular, the authors note that patent and regulatory exclusivity provisions are likely to remain the core approach, but other voluntary incentives, such as prizes and "opt-in" programs, can play a useful role in addressing unmet needs and gaps in targeted circumstances when market incentives are inadequate.
Read the article (subscription required)